Singapore, June 9 -- China-based Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., for the development, registration and commercialisation of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China.

Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.

This collaboration strengthens the company's cardiovascular portfolio and highlights Everest's continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy a...